A Peptide-Directed siRNA Delivery Platform for Glioblastoma Multiforme: Targeting Genes Driving Treatment Resistance

Overview

ProteinQure is a revenue-generating (over $20M CAD total), clinical-stage biotech company developing peptides for precision therapeutic delivery. They combine machine learning and generative AI to design best-in-class therapeutics, both through fee-for-service partnerships with large pharmaceutical companies and via an internal drug discovery pipeline.

PQ203, is a peptide-drug conjugate for triple-negative breast cancer, now in a Phase I clinical trial at Princess Margaret Cancer Centre in Toronto. ProteinQure has experience across 80+ clinical trials and advanced PQ203 from discovery to IND-enabling studies in just two years—and into clinical trials 18 months later—demonstrating exceptional execution in translating preclinical programs into clinical assets.

Building on the innovation of PQ203, an AI-designed SORT1-binding peptide, they further modified and optimized this scaffold for CNS delivery of therapeutic payloads, having the potential to unlock an estimated $100B global market across neurology and neurodegenerative disease indications.

The CNS-delivery program leverages this optimized SORT1-binding peptide to deliver siRNA molecules for targeted gene knockdown in the brain. The program is supported by an advanced data package: best-in-class delivery across multiple in vivo models, including rodents and, more recently, non-human primates. For the lead CNS indication, they selected Glioblastoma Multiforme (GBM), a lethal brain cancer with relatively high incidence in Canada and few effective treatment options.

The interest in glioblastoma (GBM) is guided by ProteinQure’s existing expertise in cancer biology and, importantly, through a partnership with Dr. Stéphane Angers, Director of the Donnelly Centre at the University of Toronto and an internationally recognized leader in GBM genetics. Dr. Angers brings unparalleled leadership, drug development experience, and state-of-the-art tools that will support the advancement of our therapeutic candidate for GBM.

Also on the project team is Dr. Peter Dirks, a world-renowned neurosurgeon at SickKids and pioneer in brain cancer stem cell biology, whose lab has developed and validated in vivo GBM models. Dr. Douglas Cook, Professor and Chair of Neurosurgery at Queen’s University, adds expertise in translational neuroscience and access to a world-class non-human primate facility with established models for CNS therapeutics.

ProteinQure has a proven track record advancing oncology programs into the clinic, and unlike more prevalent diseases such as Alzheimer’s, GBM represents an area to independently advance and commercialize a program. By leveraging Toronto’s world-class ecosystem in GBM and oncology clinical trials, the same roadmap that was successfully executed with PQ203 can be applied to develop and commercialize a life-changing therapy for patients with GBM, who face a dire need for new treatment options.

SmartRequisition: Scalable Genomic Test Requisitions

Overview

Genomic medicine is entering mainstream care, but interpretation remains a critical bottleneck: accurate variant analysis depends on structured phenotypes, yet requisitions are often incomplete, unstructured, and still on paper.

Manual entry of Human Phenotype Ontology (HPO) codes is slow, inconsistent, and labour-intensive, delaying care and limiting scalability as sequencing expands across specialties. This project will advance SmartRequisition, a software portal that automates HPO capture at ordering and generates HL7 FHIR/LIS-ready requisitions.

By Month 24, it will be implemented at IWK Health and partner Canadian sites, with a 67% reduction in phenotype coding time, 80% requisition completeness, and a solution with 30% attach-rate goal across current deployments and an ARR trajectory toward ~CA$6M.

To address the existing need, the Clinical Intelligence for Phenotyping and Genomics Research (CIPHER) network has been established. Co-led by PhenoTips and IWK Health, partners include Alberta Health Services, CHU Sainte-Justine, CHEO, and SickKids. The network will co-design and validate SmartRequisition, embedding it into intake workflows.

Using large language models with retrieval-augmented generation, the tool extracts HPO terms from free text and structured inputs, supports multimodal data, and enables clinician-in-the-loop review. Requisitions export via HL7 FHIR, LIS, or PDF for integration into lab and EHR systems.

The market opportunity is significant. The global genetic testing market was US$11.9B in 2024 and is projected to reach US$91.3B by 2034 (22.6% CAGR). Growth depends on digital infrastructure that enables high-quality requisition and interpretation. PhenoTips already serves 26 hospitals worldwide with its genomic workflow platform, anchoring an immediate ~CA$200M addressable market in hospitals with in-house genetics labs.

SmartRequisition strengthens PhenoTips’ AI-driven suite, positioning the company to capture this segment and expand into the ~CA$2B serviceable market of large health systems, with future application in oncology, neurology, cardiology, and population health.

IWK was the first centre in Atlantic Canada to deliver local clinical exome services, with phenotypes integrated into sequencing through a multi-year development and privacy/legal program. This foundation de-risks the project, allowing immediate focus on validation and roll-out within the two-year GAPP timeframe.

For Canada, SmartRequisition strengthens national genomic capacity, reduces reliance on foreign software, and improves patient care. For the CIPHER network, it supports more timely diagnoses while demonstrating a solution that can scale across provinces. By transforming a universal bottleneck into a validated product, SmartRequisition positions Canada as a leader in digital infrastructure for precision medicine.

Regional Genomic Applications Partnership Program (GAPP)

Regional Genomic Applications Partnership Program (GAPP)

Ontario Genomics’ Regional GAPP:
Fuelling Ontario’s Next Generation of Biotech Spinouts

Ontario Genomics is launching our Regional Genomic Applications Partnership Program (GAPP) to accelerate the commercialization of academic discoveries into made-in-Ontario biotech solutions.

Ontario is home to world-class researchers and institutions producing groundbreaking discoveries, yet many of them fail to progress beyond the lab. That’s because spinout companies (formed to commercialize academic intellectual property) that bring these innovations to market are often stifled by insufficient access to capital, long commercialization timelines and limited business expertise.

Ontario Genomics’ Regional GAPP is addressing these challenges by supporting spinouts at this critical lab-to-company technology transfer stage, facilitating R&D capacity, independence from academia and positioning them for seed financing. The end results will fuel job creation, company retention, IP generation and attract foreign investment, while reinforcing Ontario’s economic resilience and global reputation in genomics innovation.

In support of the Canadian Genomics Strategy, and as part of their broader GAPP initiative, Genome Canada has provided $4 million over four years to the Ontario Genomics Regional GAPP. The Ontario Ministry of Colleges, Universities, Research Excellence and Security (MCURES) has committed to match the Genome Canada contribution through the Ontario Research Fund (ORF) for the 2025 round, pending Ministry’s approval of projects.

Program Objectives:

  • Accelerate/facilitate translation of products, platforms or IP from an academic lab into a company in support of commercialization, company benefits, Ontario’s economy and made-in-Ontario IP.
  • Position early-stage Ontario companies to raise follow-on funding at project end.
  • Develop business acumen in post-graduate trainees to build a pool of highly qualified personnel (HQP) to lead the next wave of biotech companies in Ontario.
  • Position Ontario as a hub for the creation, growth and scaling of biotech innovation.

Eligibility Criteria:

  • The genomics-based/enabled project supports the invention, development or commercialization of a biotech innovation with a clearly articulated market opportunity.
  • The project is driven by a spinout company in partnership with an Ontario-based researcher and will facilitate translation of IP from academia into the commercialization pathway.
  • The spinout company is incorporated, Canadian-owned, and based in Ontario.
  • The spinout company stage is pre-seed or earlier.
  • The spinout company has at least two employees (including executives). If the lead project researcher is also the CEO, the company’s governance board must have at least one additional member.
  • The project has the potential to generate social and economic benefits for the company and Ontario.

If you meet the above criteria, please fill out this intake form.

Funding and Term:

  • The project term is 1-2 years (no extensions).
  • Four projects will be funded per year.
  • Project budget will be a minimum of $667,734:
    • $222,578 from Genome Canada
    • $222,578 from MCURES/ORF (conditions apply – see Program Guide for details)
    • ≥$222,578 from the private sector (cash or in-kind)

Canadian Biotechnology Innovation and Commercialization

Canadian Biotechnology Innovation and Commercialization (CBIC)

Canadian Biotechnology Innovation and Commercialization (CBIC)

Biotechnology leverages biological processes, organisms, or systems to develop products and technologies for a wide range of sectors, including medicine, agriculture, and environmental science, with the potential to address global challenges and enhance quality of life. The field has been significantly revolutionized by genomics, which provides a deeper understanding of the genetic basis of life. This has enabled precise manipulation and understanding of biological systems at a molecular level, driving innovation across multiple sectors.

Genome Canada has announced a strategic investment in commercialization and adoption of genomics and genomics-driven biotechnology solutions, through the Canadian Biotechnology Innovation and Commercialization (CBIC) initiative. CBIC funds public-private research and development projects that amplify the value of public investment in innovation and accelerate the commercialization of Canadian genomics inventions and innovations by addressing real-world needs and opportunities identified by industry.

This first investment in support of the Canadian Genomics Strategy aims to accelerate commercialization and adoption to address urgent health and industry challenges in Canada.

Prostate Cancer Predict

Overview

Reducing the need for prostate biopsies by predicting the risks of high grade prostate cancer (HGPrCa) using biomarkers from semen

Preventing 6,000 unnecessary biopsies: A Canadian innovation in prostate cancer diagnosis

 New prostate cancer testing targets more precise, less invasive diagnosis of the most diagnosed cancer among men in Canada.

Every year, around 100,000 men in Canada undergo prostate biopsies based on elevated PSA levels or abnormal prostate exams. They face an uncomfortable procedure that comes with risks of its own and yet only 20 per cent of those biopsies reveal high-grade prostate cancer, the kind that is clinically significant and requires treatment.

Healthcare providers need a reliable, non-invasive test to identify who needs a biopsy and who does not. Apart from MRI, there have not been non-invasive tests that can be used to reduce biopsy rates.

A genomics-driven solution

This is where FlowLabs, a Canadian diagnostic company, identifies a significant opportunity, working in collaboration with the Murray Koffler Urologic Wellness Centre and the Lunenfeld-Tanenbaum Research Institute at the Mount Sinai Hospital, the Donnelly Centre for Cellular and Biomedical Research at the University of Toronto, and the Ontario Institute for Cancer Research. FlowLabs is preparing to validate a new test that uses semen samples to identify high-grade prostate cancer. The test measures biomarkers—two amino acid metabolites and two microRNAs – that can accurately differentiate serious prostate cancer cases from low-grade prostate cancer or the absence of disease.

First, FlowLabs will confirm the validity of the test using samples from 250 men who have already had biopsies. Then, the lab will develop an algorithm that combines semen biomarker levels and other clinical data, such as PSA levels and MRI results, to predict the risk of high-grade prostate cancer more accurately. A large-scale clinical trial of 700 men undergoing biopsies at seven clinical centers across Canada will test the algorithm’s usefulness and performance in the real world.

FlowLabs is ideally equipped for this project. Based in Ontario, it has Canada-wide logistics in place for receiving samples at its central licensed laboratory. If successful, the test could allow FlowLabs to expand its workforce by the creation of as many as 50 new highly skilled positions as it taps into a North American market that is worth up to $300 million for such a test. In the next three–five years, this semen-based test could prevent up to 6,000 men from unnecessary biopsies, save the health system $8M annually, and position Canada as a global leader in non-invasive cancer diagnostics.

This test is expected to be highly attractive to patients, two-thirds of those under the age of 65 who prefer providing a semen sample to a blood sample. It has superior accuracy to other commercial tests.

FlowLabs will engage key opinion leaders and healthcare providers to support the test’s adoption, focusing on establishing reimbursement agreements with provincial healthcare systems and private insurers. The test will be initially launched across Canada, with subsequent expansion internationally.

Genome Canada’s investment in this project, and initial seed funding from the Koffler Foundation, will help unlock its potential to revolutionize prostate cancer diagnosis in Canada and globally.

Genomic Applications Partnership Program (GAPP) – 2025-2028

Genomic Applications Partnership Program (GAPP)

GAPP 2026 is now Open for Applications

As part of the Canadian Genomics Strategy (CGS), the Genomic Applications Partnership Program (GAPP) helps commercialize research across the country by supporting Canadian for-profit companies that are partnered with Canadian researchers. GAPP objectives:

  • Increase Canadian private-sector investment in the commercialization of innovation derived from public R&D funding in genomics and biotechnology.
  • Stimulate technological innovation and implementation through co-operative R&D between research and receptors.
  • Enable research investments that de-risk opportunities and secure follow-on funding from finance and industry.
  • Foster and encourage participation in innovation and entrepreneurship by individuals from equity-deserving communities.

Each GAPP project must be led by an industry receptor that is a Canadian for-profit enterprise and carried out in partnership with a researcher.

Deadline to submit a Letter of Intent is May 8, 2026.

Eligibility Criteria:

  • The program is designed to support Canadian for-profit enterprises (FPEs), known as a Receptor, that have an economic interest in developing an idea or research into a commercial application.
  • Each project must be a partnership between an industry receptor and researcher, with active roles for each, with optional support from one or more co-investigators and/or collaborators.
  • If the researcher has a position with the receptor, the receptor must have clear decision-making processes that are independent of the researcher.

Funding and Term:

  • Total project budget can be $900,000 – $6,000,000.
  • Applicants can request up to one-third of the project budget from Genome Canada.
  • Genome Canada’s total contribution to an approved project must be at least $300,000. Its maximum contribution is $2 million.
  • NEW: Receptor organizations can receive up to 20% of the Genome Canada funding contribution.
  • Private sector contributions towards the project must match or exceed the total Genome Canada contribution.
  • Projects must be completed within two years of the start date. No extensions will be granted.
Learn more of previous rounds of funded Ontario GAPP Projects.

Previous Funded Projects – Genomic Applications Partnership Program (GAPP)

Funded Ontario GAPP Projects

With funding from the Canadian Genomics Strategy (CGS), Genomic Applications Partnership Program (GAPP) is designed to support Canadian for-profit enterprises that have an economic interest in developing an idea or research into a commercial application.

Previous Rounds of National Genomic Applications Partnership Program (GAPP)

One Health Approach to Surveillance of Antimicrobial Resistance and Emerging Climate-Related Health Threats using eDNA and eRNA Tools

Overview

Environmental DNA (eDNA)/RNA (eRNA) is the genetic material organisms leave behind in their environment, including in water, soil and air.

Antimicrobial resistance (AMR) infections—where bacteria, viruses, fungi and parasites become resistant to the medications designed to kill them—pose significant health and economic challenges for Canada and the world.
This project is tackling AMR by developing an innovative and cost-effective monitoring system using wastewater-based surveillance and livestock samples, which can be analyzed to detect genes associated with AMR.

By utilizing environmental eDNA to detect AMR genes in the samples, this project will provide a broader understanding of resistance patterns within communities. The goal is to establish correlations between environmental and clinical AMR data, creating a comprehensive approach to monitoring and managing AMR in Canada.

This project will develop a portable “Lab-in-a-Box” system to enable rapid, onsite detection of eDNA (AMR genes) in wastewater. This tool will be particularly valuable for remote and underserved regions, as it preserves sample integrity and provides faster results than traditional methods, which often require shipping samples to centralized labs. The project will also develop an Ethical and Inclusive Governance Framework to ensure that eDNA data collection and analysis in Indigenous communities respects their rights and is conducted in a culturally sensitive manner.

The project will:

  • Optimize and validating new eDNA-based tools to enhance AMR surveillance at local and national levels. Public health officials, including Ontario Public Health Units (PHUs) and the Public Health Agency of Canada (PHAC), will have access to near real-time data on AMR trends. This will enable them to detect AMR hotspots, implement targeted interventions and adjust antimicrobial use policies, and in keeping with the Governance Framework to ensure Indigenous rights are respected.
  • By providing evidence-based data, help expand the use of eDNA technologies as surveillance tools, optimize antibiotic use, reduce treatment failures and curb the spread of AMR, improving health outcomes and reducing healthcare costs across Canada.
  • Provide opportunities for collaboration to foster a continuous exchange of knowledge between clinical and environmental surveillance systems. This comprehensive approach will significantly improve Canada’s ability to respond to AMR and guide public health efforts to combat this growing global health crisis.

One Health Surveillance of Emergent and Climate Change Health Threats in Southern and Northern, Remote and Isolated First Nations

Overview

Environmental DNA (eDNA)/RNA (eRNA) is the genetic material organisms leave behind in their environment, including in water, soil and air.

Rising temperatures are increasing the health risks posed by disease vectors, such as ticks and mosquitos. For Indigenous communities, these risks are compounded by significant health disparities, geographical isolation and mistrust of health-care systems rooted in colonial practices. Traditional medical testing also often proves intrusive, costly and impractical for remote First Nations.

This project will help support health resilience and equity for two First Nations communities in Ontario through development and implementation of new eDNA/eRNA tools for wastewater and environmental monitoring.

These innovative tools will enable systematic collection, analysis and interpretation of community wastewater to monitor zoonotic and vector-borne diseases, which are increasingly prevalent due to climate change. To ensure this project serves community needs and cultures, it is adopting a co-development model with Indigenous partners, prioritizing community rights, interests and expectations.

This project will:

  • Integrate environmental, wildlife and public health data into a “One Health” approach, ensuring human, animal and environmental health are monitored cohesively.
  • Work to ensure the application of wastewater and environmental monitoring tools will align with Indigenous values, avoiding data colonialism. To achieve this, the project will adopt a co-development model with Indigenous partners, prioritizing community rights, interests, and expectations.
  • In collaboration with community stakeholders and partners—including Environment and Climate Change Canada, the Canadian Food Inspection Agency, the Feather Board Command Centre, and the Ontario Ministry of Agriculture, Food and Agribusiness —the project will develop culturally appropriate frameworks based on the First Nations principles of Ownership, Control, Access, and Possession (OCAP). These frameworks will guide the ethical and sustainable use of eDNA and eRNA tools, ensuring the generated data directly benefits the communities while respecting Indigenous sovereignty.
  • Drive development of sensitive, accurate and rapid eDNA and eRNA analytical methods to enhance the detection of avian-borne, vector-borne and zoonotic diseases, enabling timely public health responses.
  • By supporting Indigenous data sovereignty and OCAP principles, empower communities to independently manage their health data, strengthening local capacity for disease surveillance and response while fostering Indigenous leadership in health resilience.

eDNA Surveillance Initiative

eDNA Surveillance Initiative

eDNA Surveillance can tell us nature’s secrets

As humans, we don’t live in a bubble. We’re connected to all living things around us, so it only makes sense to better understand the impact humans, animals and the environment have on each other. That’s where Environmental DNA (eDNA) comes in!

This advanced surveillance technique is emerging as a non-invasive method to better understand how our changing climate is impacting all living things, especially human health. Ontario Genomics is funding two new projects through Genome Canada’s eDNA Surveillance Initiative that gives regional support to better develop more sensitive and accurate detection methods.

One project will help two First Nations communities develop and implement new eDNA/eRNA tools for wastewater and ecological monitoring, while the other will track and correlate environmental and clinical antimicrobial resistance. An ethical and inclusive governance policy framework will be co-created with First Nations communities to ensure privacy protection, confidentiality and data integrity while respecting Indigenous sovereignty.